Skip to main content
Horizon Europe
Geographic overview of consortium partners

The partners divided in the work packages

partners divided by work package
WPTitle WPLeader WP
1Maximising data usage with artificial intelligenceUGent – Kevin Van Geem
2Development of biodegradable compoundsLEU – Klaus Kümmerer
3Greening pharmaceutical productionUGent – Chris Stevens
4Integrated sustainability assessmentRU – Ad Ragas
5Preparing for the transition to greener pharmaceuticalsRIVM – Bastiaan Venhuis
6Stakeholder engagement, communication, dissemination, exploitation and training activitiesEcologic – Rodrigo Vidaurre
7Project ManagementUGent – Chris Stevens

Project partners and financing

Flag of the EUFunded by the European Union

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101057816 – TRANSPHARM

Partners

TransPharm’s consortium consists in 12 partners from 9 EU countries (Belgium, The Netherlands, Finland, Germany, Norway, Ireland, France, Latvia and UK).

Ghent University

Belgium

https://www.ugent.be/en

Main role in the project

  • The coordination of this project
  • Artificial intelligence (WP1)
  • Ecotoxicology (WP2)
  • Flow chemistry approach (WP3)
  • Life cycle assessment (LCA) and environmental risk assessment (ERA) (WP4)
  • Transition towards greener pharmaceuticals (WP5)
  • Communication and dissemination (WP6)
  • Project management (WP7)

Helsingin Yliopisto (University of Helsinki)

Finland

https://www.helsinki.fi/en

Expert in green chemistry and sustainable pharmacy

Main role in the project

UH works towards

  • The reduction of contamination on APIs,
  • Develops improved biodegradation testing,
  • And examines the hepatic metabolism of API and their (bio)transformation products in human and fish.

Circa

Norway

www.circa-group.com

Expert in the produciton of bio-based chemicals from waste feedstocks on scale

Main role in the project

Circa Group will develop succinict synthetic routes to pharmaceuticals using our bio-based platform molecule levoglucosenone (LGO).

Radboud University Nijmegen (RU)

The Netherlands

https://www.ru.nl/

Expert in environmental modelling and sustainability assessment

Main role in the project

RU develops approaches and tools to assess the sustainability of pharmaceuticals.

Leuphana University of Lüneburg

Institute of Sustainable Chemistry
Chair for Sustainable Chemistry and Material Resources

Germany

https://www.leuphana.de
https://www.leuphana.de/en/institutes/insc.html
https://www.leuphana.de/en/institutes/insc/nachhaltige-chemie-und-ressourcen-englisch.html

Experts in biodegradability and the development of environmentally benign pharmaceuticals and ionic liquids

Main role in the project

Leuphana is overseeing the

  • development of environmentally benign fluoroquinolone antibiotics (WP2)
  • and is responsible for assessing the most promising new molecules.

University of York

UK

https://www.york.ac.uk/

World-leading academic facility for pioneering pure and applied green and sustainable chemical research.

Main role in the project

UoY works towards

  • Developing the activities of screening new solvents,
  • Development of a new sustainability score for production processes and
  • Developing training materials.

KelAda Pharmachem

Ireland

https://www.keladapharmachem.com

Experts in process chemistry and medicinal chemistry

Main role in the project

KelAda develops novel toolboxes of biobased platform molecules and exemplifies their utility through their application as starting materials in the synthesis of pharmaceuticals.

Orion

Finland

https://www.orion.fi/en/

Orion is a globally operating Finnish pharmaceutical company.

Main role in the project

Orion will provide industrial guidance and expert advice how the developed tools fit into the pharmaceutical industry processes from early MedChem scale to API production scale.

RIVM

The Netherlands

https://www.rivm.nl/en/about-rivm

RIVM, the Dutch National Institute for Public Health and the Environment, works towards a healthy population living in a sustainable, safe and healthy environment. RIVM pursues those goals based on independent scientific research.

Main role in the project

RIVM is involved in WP2-6 and they will be leading the WP5 and developing activities as filling data gaps in LCI, developing methodology to compare pharmaceutical ingredients and products (WP4), business case studies for greener pharmaceuticals (WP5), and education modules (WP6).

Ecologic Institute

Germany

https://www.ecologic.eu

Ecologic Institute is an independent research institution for environmental research and policy analysis. Since its founding in 1995, Ecologic Institute has been dedicated to improving environmental policy, sustainable development and policy practice. We strengthen the European and international dimensions in research, education and environmental policy discourse.

Main role in the project

Ecologic Institute is leading Work Package 6 - Stakeholder engagement, communication, dissemination, exploitation and training activities, using its broad knowledge of the design and implementation of stakeholder engagement and communication processes. Beyond WP6, Ecologic Institute also participates in WP4 – Integrated sustainability assessment and WP5 – Preparing for the transition to greener pharmaceuticals.

Advisory Board

Logo Sustainable Healthcare Coalition
Logo Health Care Without Harm
Logo European Federation of Pharmaceutical Industries and Associations
Logo Boehringer Ingelheim
Logo Janssen Pharmaceuticals
Logo TAKEDA